Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma
To distinguish prognostic subgroups patients with aggressive B cell lymphoma, we analyzed 800 MIRNAS’s expression with Nanostring NCounter Micna Mirna Test on cohort 228 FFPE samples of patients registered in the Ricover-60 trial and megachoep. We identify significant Mirna signatures for the overall survival (OS) (OS) and progressive free survival (PFS) with linear cox regression punished by Laso. The level of high expression of the MIR-130A-3P and MIR-423-5P shows a better prognosis, while the high level of MIR-374B-5P, MIR-590-5P, MIR-186-5P, and MIR-106B-5P-5P increases Patients’ risk level for OS.
Regarding the PFS high expression MIR-365A-5P In addition to two other MIRNAS increases the prognosis and high level of MIR374A-5P, MIR-106B-5P, and MIR-590-5P, connected with an increased risk and poor prognosis. We identified the signature of Mirna to divide patients into two different risk groups. This prognostic model can be used in risk stratification in clinical trials in the future and helps make personalized therapeutic decisions.
Comparative analysis of transcript profile, proteome, and mirna cupffer cells and monocytes
The macrophage population in most mammalian organs consists of different origin cells. The macrophage of the population comes from the erythromiseloid precursor of the wall of the egg yolk bag; Maintenance of the amount of macrophages in the postnatal ontogenesis is practically independent of the hematopoiesis bone marrow. The largest population of the population of embryonic population is found in the central nervous system (Mikroglia) and the liver (Cell Cupffer). Conversely, dermis and mucous membranes become largely colonized by monocytes of bone marrow derivatives which show clear and phenotical plasticity.
In this study, we compare cupffer cells and monocytes using immunofenotype, gene expression profiles, proteome, and microrna collections. The observed difference does not consider the macrophage of the residents’ hearts as pure m2 macrophages or the situation owned by a monocyte has a pure M1 feature. Monocytes show signs of high plasticity and sensitivity to the pattern of molecules related to pathogens (for example, high transcription rates for <i> TLR 2 </ i>, <i> 4 </ i>, <i> 7 </ i>, and <i> 8 </ i>). Conversely, the macrophage of the Heart of the population is clearly involved in the regulations of certain organ functions (nitrogen metabolism, a complementary system protein synthesis).
PMDNE: Prediction of the Mirna-Disease Association based on network embedding and network similarity analysis
Prediction of success from the Mirna-Disease Association is nontrivial for the diagnosis and prognosis of genetic diseases. There are many methods for predicting mirna and disease, but many biological data and complex, and they are often in network form. Ways to accurately use MIRNA features and biological tissue related to diseases to predict unknown associations always become a challenge. Here, we propose PMDNE, a method based on network embedding and network similarity analysis, to predict Mirna’s associations.
At PMDNE, the structure of bipartite graphics network is improved, and the generator runs randomly designed. For embedded vectors, 128 dimensions are used, and predictive accuracy increases significantly. Compared to other network embedding methods, PMDNE is comparable and competitive with the method of art conditions. The method we can solve features extraction features, reduce the dimensions of features, and increase the efficiency of predictions of mirna-disease associations. This method can also be extended to other areas for biomedical tissue predictions.
Effect of lifestyle factors on mirna expression and signal paths: reviews
The term ‘lifestyle’ includes various factors that contribute to maintenance of good health status. Increased evidence shows that lifestyle factors can affect epigenetic mechanisms, such as MIRNAS’s expression. MIRNA dysregulation can modify gene expression and molecular pathways that can cause functional changes. This review summarizes human studies that highlights that diet, physical activity, smoking consumption and alcohol can affect the Mirna engine and some biological functions.
Most Mirnas are involved in molecular lines that affect inflammation, cell cycle regulations and carcinogenesis produce onset or the development of pathological conditions. Investigating this interaction will be very important to understand the etiology of the pathological process, the potential for new care strategies and to prevent disease.
From the Mirna target network to the Mirna function: MIR-375 can regulate apoptosis and dynamics of actin in the heart muscle through the path that depends on RHO-GTPASES
Micrornas (MIRNAS) is a short ribonucleic acid molecule (RNA), without code, which is involved in the main biological process regulations, such as apoptosis or proliferation and cell differentiation, through specific interactions of sequences with the MRNAS target. In this study, we propose workflows to predict the MIRNA function by analyzing their target gene network structure. This workflow is applied to study the functional role of the MIR-375 in the heart of the muscle (myocardium), because Mirna previously proved to be associated with heart disease, and the data on its functions in myocardium was largely unclear.
Hygromycin B |
H007-1G |
TOKU-E |
1 g |
EUR 120 |
Hygromycin B |
H007-500MG |
TOKU-E |
500 mg |
EUR 81.6 |
Hygromycin B |
H007-5x1G |
TOKU-E |
5 x 1 g |
EUR 384 |
Hygromycin B |
2589-1000 |
Biovision |
each |
EUR 314.4 |
Hygromycin B |
2589-500 |
Biovision |
each |
EUR 235.2 |
HYGROMYCIN B SOLUTION |
30-240-CR |
CORNING |
20 mL/pk |
EUR 188.4 |
Description: Media Catalog; Cell Culture Reagents |
Hygromycin B Concentrated |
H001-1MU |
TOKU-E |
1 MU |
EUR 116.4 |
EZSolution? Hygromycin B |
2590-20 |
Biovision |
each |
EUR 326.4 |
Hygromycin B, 10g |
R3128-10g |
ACTGene |
each |
EUR 2724 |
Hygromycin B, 1g |
R3128-1g |
ACTGene |
each |
EUR 362.4 |
Hygromycin B EvoPure® |
H010-1G |
TOKU-E |
1 g |
EUR 225.6 |
Hygromycin B EvoPure® |
H010-500MG |
TOKU-E |
500 mg |
EUR 172.8 |
Hygromycin B EvoPure (Low Endotoxin) |
H024-1G |
TOKU-E |
1g |
EUR 650.4 |
Hygromycin B EvoPure (Low Endotoxin) |
H024-500MG |
TOKU-E |
500 mg |
EUR 415.2 |
Hygromycin B Solution (Low Endotoxin) |
H026-20ML |
TOKU-E |
20 mL |
EUR 142.8 |
Hygromycin Antibody |
abx023698-1mg |
Abbexa |
1 mg |
EUR 1312.8 |
|
Hygromycin Antibody |
abx023699-1mg |
Abbexa |
1 mg |
EUR 1312.8 |
|
Escherichia coli Hygromycin-B 4-O-kinase (hph) |
1-CSB-EP365448ENL |
Cusabio |
-
EUR 733.20
-
EUR 370.80
-
EUR 2192.40
-
EUR 1126.80
-
EUR 1461.60
-
EUR 476.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Escherichia coli Hygromycin-B 4-O-kinase(hph) expressed in E.coli |
Escherichia coli Hygromycin-B 4-O-kinase (hph) |
1-CSB-EP365448ENLa0 |
Cusabio |
-
EUR 733.20
-
EUR 370.80
-
EUR 2192.40
-
EUR 1126.80
-
EUR 1461.60
-
EUR 476.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Escherichia coli Hygromycin-B 4-O-kinase(hph) expressed in E.coli |
Escherichia coli Hygromycin-B 4-O-kinase (hph) |
1-CSB-YP365448ENL |
Cusabio |
-
EUR 814.80
-
EUR 402.00
-
EUR 2606.40
-
EUR 1261.20
-
EUR 1730.40
-
EUR 522.00
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Escherichia coli Hygromycin-B 4-O-kinase(hph) expressed in Yeast |
Hygromycin phosphotransferase antibody |
10-1418 |
Fitzgerald |
1 mg |
EUR 813.6 |
Description: Mouse monoclonal Hygromycin phosphotransferase antibody |
Hygromycin phosphotransferase antibody |
10-1419 |
Fitzgerald |
1 mg |
EUR 813.6 |
Description: Mouse monoclonal Hygromycin phosphotransferase antibody |
Hygromycin phosphotransferase antibody |
10-1420 |
Fitzgerald |
1 mg |
EUR 813.6 |
Description: Mouse monoclonal Hygromycin phosphotransferase antibody |
Hygromycin phosphotransferase antibody |
10-1421 |
Fitzgerald |
1 mg |
EUR 813.6 |
Description: Mouse monoclonal Hygromycin phosphotransferase antibody |
Hygromycin B Solution (50 mg/ml in PBS Buffer) |
H011-20ML |
TOKU-E |
20 mL |
EUR 133.2 |
Hygromycin B Solution (50 mg/ml in PBS Buffer) |
H011-5x20ML |
TOKU-E |
5x20mL |
EUR 440.4 |
Hygromycin B EvoPure Solution (100 mg/ml in PBS Buffer) |
H015-10x2ML |
TOKU-E |
10 x 2 mL |
EUR 340.8 |
Hygromycin B EvoPure Solution (100 mg/ml in PBS Buffer) |
H015-5x2ML |
TOKU-E |
5 x 2 mL |
EUR 225.6 |
Cas9 Lentivirus (Hygromycin Selection) |
78067 |
BPS Bioscience |
500 µl x 2 |
EUR 795 |
Description: Cas9 Lentivirus can be used to generate Cas9 expressing cells in almost any mammalian cell line. Cells stably expressing Cas9 can then be transduced or electroporated with sgRNA targeting a gene of interest to quickly generate knock-out cell pools or cell lines.
The Cas9 Lentiviruses are replication incompetent, HIV-based VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a Cas9 gene driven by an EF1a promoter, along with a Hygromycin selection marker._x000D_ |
Enhanced GFP Lentivirus (Hygromycin) |
78639-H |
BPS Bioscience |
500 µl x 2 |
EUR 835 |
Description: Enhanced green fluorescent protein (eGFP) is a modified (F64L and S65T mutations) version of the native GFP protein isolated from jellyfish (Aequorea victoria), with increased fluorescence and more efficient folding. The Enhanced GFP Lentivirus are replication-incompetent, HIV based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express eGFP under a CMV promoter. eGFP expression and transduction efficiency can easily be verified and optimized via fluorescence microscopy or flow cytometry. eGFP has an excitation wavelength of 488 nm, an emission wavelength of 509 nm, and extinction coefficient of 55,000 M-1cm-1. |
Firefly Luciferase Lentivirus Hygromycin |
79692-H |
BPS Bioscience |
500 µl x 2 |
EUR 875 |
Description: The Firefly Luciferase Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. These viruses constitutively express firefly luciferase under a CMV promoter. |
Fmoc-b,b-diphenyl-Ala-OH |
B-2725.0250 |
Bachem |
250.0mg |
EUR 166.8 |
Description: Sum Formula: C30H25NO4; CAS# [201484-50-6] |
Fmoc-b,b-diphenyl-Ala-OH |
B-2725.1000 |
Bachem |
1.0g |
EUR 428.4 |
Description: Sum Formula: C30H25NO4; CAS# [201484-50-6] |
Fmoc-b,b-diphenyl-Ala-OH |
B-2725.5000 |
Bachem |
5.0g |
EUR 1603.2 |
Description: Sum Formula: C30H25NO4; CAS# [201484-50-6] |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His, Yeast-100ug |
QP7397-ye-100ug |
EnQuireBio |
100ug |
EUR 945.6 |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His, Yeast-10ug |
QP7397-ye-10ug |
EnQuireBio |
10ug |
EUR 434.4 |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His, Yeast-1mg |
QP7397-ye-1mg |
EnQuireBio |
1mg |
EUR 3296.4 |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His, Yeast-200ug |
QP7397-ye-200ug |
EnQuireBio |
200ug |
EUR 1512 |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His, Yeast-500ug |
QP7397-ye-500ug |
EnQuireBio |
500ug |
EUR 2164.8 |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His, Yeast-50ug |
QP7397-ye-50ug |
EnQuireBio |
50ug |
EUR 576 |
MEF Feeder Cells (Hygromycin-resistant) |
CBA-313 |
Cell Biolabs |
1 vial |
EUR 553.2 |
Description: MEF Feeder Cells are mouse embryonic fibroblasts that allow stem cell culture without LIF. Cells must be mitotically inactivated prior to addition of stem cells. Hygromycin resistant. |
Expression Negative Control Lentivirus (Hygromycin) |
79902-H |
BPS Bioscience |
500 µl x 2 |
EUR 795 |
Description: The Expression Negative Control Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The controls package the same virus particles as the target expression virus, but they do not express a specific protein under the CMV promoter. _x000D_The Expression Negative Control Lentivirus (G418) expresses the gene for aminoglycoside 3' phosphotransferase, which confers resistance to kanamycin, neomycin, and geneticin (G418)._x000D_The Expression Negative Control Lentivirus (Hygromycin) expresses the gene for hygromycin B phosphotransferase, which confers resistance to Hygromycin._x000D_The Expression Negative Control Lentivirus (Puromycin) expresses the gene for puromycin N-acetyl-transferase, which confers resistance to puromycin._x000D_ _x000D_ |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His-SUMO, E.coli-100ug |
QP7397-ec-100ug |
EnQuireBio |
100ug |
EUR 848.4 |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His-SUMO, E.coli-10ug |
QP7397-ec-10ug |
EnQuireBio |
10ug |
EUR 391.2 |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His-SUMO, E.coli-1mg |
QP7397-ec-1mg |
EnQuireBio |
1mg |
EUR 2763.6 |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His-SUMO, E.coli-200ug |
QP7397-ec-200ug |
EnQuireBio |
200ug |
EUR 1338 |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His-SUMO, E.coli-500ug |
QP7397-ec-500ug |
EnQuireBio |
500ug |
EUR 1816.8 |
Recombinant E.coli Hygromycin-B 4-O-kinase Protein, His-SUMO, E.coli-50ug |
QP7397-ec-50ug |
EnQuireBio |
50ug |
EUR 522 |
Fmoc-b-Ala-OPfp |
B-1765.0005 |
Bachem |
5.0g |
EUR 283.2 |
Description: Sum Formula: C24H16F5NO4; CAS# [149303-38-8] |
Fmoc-b-Ala-OPfp |
B-1765.0025 |
Bachem |
25.0g |
EUR 1009.2 |
Description: Sum Formula: C24H16F5NO4; CAS# [149303-38-8] |
Fmoc-b-Ala-OH |
B-1025.0005 |
Bachem |
5.0g |
EUR 138 |
Description: Sum Formula: C18H17NO4; CAS# [35737-10-1] |
Fmoc-b-Ala-OH |
B-1025.0025 |
Bachem |
25.0g |
EUR 283.2 |
Description: Sum Formula: C18H17NO4; CAS# [35737-10-1] |
Fmoc-b-Ala-OH |
B-1025.0100 |
Bachem |
100.0g |
EUR 762 |
Description: Sum Formula: C18H17NO4; CAS# [35737-10-1] |
Fmoc-b-cyclohexyl-Ala-OH |
B-1975.0001 |
Bachem |
1.0g |
EUR 151.2 |
Description: Sum Formula: C24H27NO4; CAS# [135673-97-1] |
Fmoc-b-cyclohexyl-Ala-OH |
B-1975.0005 |
Bachem |
5.0g |
EUR 501.6 |
Description: Sum Formula: C24H27NO4; CAS# [135673-97-1] |
Fmoc-b-cyclohexyl-Ala-OH |
B-1975.0025 |
Bachem |
25.0g |
EUR 1430.4 |
Description: Sum Formula: C24H27NO4; CAS# [135673-97-1] |
Fmoc-b-cyclopropyl-Ala-OH |
B-2905.0001 |
Bachem |
1.0g |
EUR 414 |
Description: Sum Formula: C21H21NO4; CAS# [214750-76-2] |
Fmoc-b-cyclopropyl-Ala-OH |
B-2905.0005 |
Bachem |
5.0g |
EUR 1561.2 |
Description: Sum Formula: C21H21NO4; CAS# [214750-76-2] |
TCR Activator Lentivirus (EF1a Promoter/Hygromycin) |
79894-EH |
BPS Bioscience |
500 µl x 2 |
EUR 795 |
Description: The TCR Activator Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a gene for a membrane-bound, engineered T cell receptor (TCR) activator driven by a CMV promoter or an EF1a promoter. After transduction, the expression of TCR activator can be monitored in the target cells. |
Fmoc-b-(2-thienyl)-Ala-OH |
B-1665.0001 |
Bachem |
1.0g |
EUR 340.8 |
Description: Sum Formula: C22H19NO4S; CAS# [130309-35-2] |
Fmoc-b-(2-thienyl)-Ala-OH |
B-1665.0005 |
Bachem |
5.0g |
EUR 1255.2 |
Description: Sum Formula: C22H19NO4S; CAS# [130309-35-2] |
Fmoc-b-(3-pyridyl)-Ala-OH |
B-2005.0001 |
Bachem |
1.0g |
EUR 471.6 |
Description: Sum Formula: C23H20N2O4; CAS# [175453-07-3] |
Fmoc-b-(3-pyridyl)-Ala-OH |
B-2005.0005 |
Bachem |
5.0g |
EUR 1778.4 |
Description: Sum Formula: C23H20N2O4; CAS# [175453-07-3] |
Fmoc-b-cyclohexyl-D-Ala-OH |
B-2345.0001 |
Bachem |
1.0g |
EUR 181.2 |
Description: Sum Formula: C24H27NO4; CAS# [144701-25-7] |
Fmoc-b-cyclohexyl-D-Ala-OH |
B-2345.0005 |
Bachem |
5.0g |
EUR 618 |
Description: Sum Formula: C24H27NO4; CAS# [144701-25-7] |
Fmoc-b-cyclohexyl-D-Ala-OH |
B-2345.0025 |
Bachem |
25.0g |
EUR 2358 |
Description: Sum Formula: C24H27NO4; CAS# [144701-25-7] |
Fmoc-b-(3-benzothienyl)-Ala-OH |
B-2830.0001 |
Bachem |
1.0g |
EUR 254.4 |
Description: Sum Formula: C26H21NO4S; CAS# [177966-60-8] |
Fmoc-b-(3-benzothienyl)-Ala-OH |
B-2830.0005 |
Bachem |
5.0g |
EUR 907.2 |
Description: Sum Formula: C26H21NO4S; CAS# [177966-60-8] |
Fmoc-b-cyclopropyl-D-Ala-OH |
B-2915.0001 |
Bachem |
1.0g |
EUR 704.4 |
Description: Sum Formula: C21H21NO4; CAS# [170642-29-2] |
Fmoc-b-cyclopropyl-D-Ala-OH |
B-2915.0005 |
Bachem |
5.0g |
EUR 2706 |
Description: Sum Formula: C21H21NO4; CAS# [170642-29-2] |
Fmoc-b-(2-quinolyl)-Ala-OH |
B-3165.0250 |
Bachem |
250.0mg |
EUR 457.2 |
Description: Sum Formula: C27H22N2O4; CAS# [214852-56-9] |
Fmoc-b-(2-quinolyl)-Ala-OH |
B-3165.1000 |
Bachem |
1.0g |
EUR 1284 |
Description: Sum Formula: C27H22N2O4; CAS# [214852-56-9] |
Fmoc-b-azido-Aib-OH · BHA |
B-4530.0001 |
Bachem |
1.0g |
EUR 846 |
Description: Sum Formula: C19H18N4O4·C13H13N; CAS# [1926163-90-7] net |
Fmoc-b-(3-pyridyl)-D-Ala-OH |
B-2040.0001 |
Bachem |
1.0g |
EUR 327.6 |
Description: Sum Formula: C23H20N2O4; CAS# [142994-45-4] |
Fmoc-b-(3-pyridyl)-D-Ala-OH |
B-2040.0005 |
Bachem |
5.0g |
EUR 1197.6 |
Description: Sum Formula: C23H20N2O4; CAS# [142994-45-4] |
Fmoc-b-(2-thienyl)-D-Ala-OH |
B-2120.0001 |
Bachem |
1.0g |
EUR 370.8 |
Description: Sum Formula: C22H19NO4S; CAS# [201532-42-5] |
Fmoc-b-(2-thienyl)-D-Ala-OH |
B-2120.0005 |
Bachem |
5.0g |
EUR 1371.6 |
Description: Sum Formula: C22H19NO4S; CAS# [201532-42-5] |
Fmoc-b-(2-quinolyl)-D-Ala-OH |
B-3170.0250 |
Bachem |
250.0mg |
EUR 529.2 |
Description: Sum Formula: C27H22N2O4; CAS# [214852-58-1] |
Fmoc-b-(2-quinolyl)-D-Ala-OH |
B-3170.1000 |
Bachem |
1.0g |
EUR 1531.2 |
Description: Sum Formula: C27H22N2O4; CAS# [214852-58-1] |
Fmoc-b-(3-benzothienyl)-D-Ala-OH |
B-3435.0001 |
Bachem |
1.0g |
EUR 400.8 |
Description: Sum Formula: C26H21NO4S; CAS# [177966-61-9] |
Fmoc-b-(3-benzothienyl)-D-Ala-OH |
B-3435.0005 |
Bachem |
5.0g |
EUR 1488 |
Description: Sum Formula: C26H21NO4S; CAS# [177966-61-9] |
Fmoc-b-(1-piperazinyl)-Ala(Boc)-OH |
B-3725.0250 |
Bachem |
250.0mg |
EUR 459.6 |
Description: Sum Formula: C27H33N3O6; CAS# [313052-20-9] |
Fmoc-b-(1-piperazinyl)-Ala(Boc)-OH |
B-3725.1000 |
Bachem |
1.0g |
EUR 1305.6 |
Description: Sum Formula: C27H33N3O6; CAS# [313052-20-9] |
Fmoc-b-azido-D-Aib-OH · BHA |
B-4535.0001 |
Bachem |
1.0g |
EUR 846 |
Description: Sum Formula: C19H18N4O4·C13H13N; CAS# [1926163-91-8] net |
Fmoc-Asn(GlcNAc(Ac)3-b-D)-OH |
B-2480.0100 |
Bachem |
100.0mg |
EUR 704.4 |
Description: Sum Formula: C33H37N3O13; CAS# [131287-39-3] |
Fmoc-Asn(GlcNAc(Ac)3-b-D)-OH |
B-2480.0250 |
Bachem |
250.0mg |
EUR 1371.6 |
Description: Sum Formula: C33H37N3O13; CAS# [131287-39-3] |
Fmoc-N-(N-b-Boc-aminoethyl)-Gly-OH |
B-3285.0001 |
Bachem |
1.0g |
EUR 544.8 |
Description: Sum Formula: C24H28N2O6; CAS# [141743-15-9] |
Fmoc-N-(N-b-Boc-aminoethyl)-Gly-OH |
B-3285.0005 |
Bachem |
5.0g |
EUR 2037.6 |
Description: Sum Formula: C24H28N2O6; CAS# [141743-15-9] |
Fmoc-Ser(GlcNAc(Ac)3-b-D)-OH |
B-3865.0025 |
Bachem |
25.0mg |
EUR 318 |
Description: Sum Formula: C32H36N2O13; CAS# [160067-63-0] |
Fmoc-Ser(GlcNAc(Ac)3-b-D)-OH |
B-3865.0100 |
Bachem |
100.0mg |
EUR 882 |
Description: Sum Formula: C32H36N2O13; CAS# [160067-63-0] |
Fmoc-Ser(GlcNAc(Ac)3-b-D)-OH |
B-3865.0250 |
Bachem |
250.0mg |
EUR 1725.6 |
Description: Sum Formula: C32H36N2O13; CAS# [160067-63-0] |
Fmoc-Ser(GalNAc(Ac)3-b-D)-OH |
B-4235.0025 |
Bachem |
25.0mg |
EUR 318 |
Description: Sum Formula: C32H36N2O13; CAS# [1676104-71-4] |
Fmoc-Ser(GalNAc(Ac)3-b-D)-OH |
B-4235.0100 |
Bachem |
100.0mg |
EUR 882 |
Description: Sum Formula: C32H36N2O13; CAS# [1676104-71-4] |
Fmoc-Ser(GalNAc(Ac)3-b-D)-OH |
B-4235.0250 |
Bachem |
250.0mg |
EUR 1725.6 |
Description: Sum Formula: C32H36N2O13; CAS# [1676104-71-4] |
Fmoc-Thr(GalNAc(Ac)3-b-D)-OH |
B-4240.0025 |
Bachem |
25.0mg |
EUR 332.4 |
Description: Sum Formula: C33H38N2O13; CAS# [133575-43-6] |
Fmoc-Thr(GalNAc(Ac)3-b-D)-OH |
B-4240.0100 |
Bachem |
100.0mg |
EUR 924 |
Description: Sum Formula: C33H38N2O13; CAS# [133575-43-6] |
Fmoc-Thr(GalNAc(Ac)3-b-D)-OH |
B-4240.0250 |
Bachem |
250.0mg |
EUR 1812 |
Description: Sum Formula: C33H38N2O13; CAS# [133575-43-6] |
Fmoc-Thr(GlcNAc(Ac)3-b-D)-OH |
B-4245.0025 |
Bachem |
25.0mg |
EUR 332.4 |
Description: Sum Formula: C33H38N2O13; CAS# [160168-40-1] |
Fmoc-Thr(GlcNAc(Ac)3-b-D)-OH |
B-4245.0100 |
Bachem |
100.0mg |
EUR 924 |
Description: Sum Formula: C33H38N2O13; CAS# [160168-40-1] |
Fmoc-Thr(GlcNAc(Ac)3-b-D)-OH |
B-4245.0250 |
Bachem |
250.0mg |
EUR 1812 |
Description: Sum Formula: C33H38N2O13; CAS# [160168-40-1] |
Fmoc-b-(7-methoxy-coumarin-4-yl)-Ala-OH |
B-3740.0500 |
Bachem |
500.0mg |
EUR 414 |
Description: Sum Formula: C28H23NO7; CAS# [524698-40-6] |
Fmoc-b-(7-methoxy-coumarin-4-yl)-Ala-OH |
B-3740.1000 |
Bachem |
1.0g |
EUR 726 |
Description: Sum Formula: C28H23NO7; CAS# [524698-40-6] |
Goat Anti-Protective Antigen 83 (PA83; B Anthracis) IgG-biotinylated |
PA16-B |
Alpha Diagnostics |
50 ug |
EUR 489.6 |
ODN 1668 -Type B murine TLR9 Agonist biotin conjugate- Antigen grade |
ODN1668-B |
Alpha Diagnostics |
Custom |
Ask for price |
ODN 1826- Type B murine TLR9 Agonist Biotin conjugate, antigen grade |
ODN1826-B |
Alpha Diagnostics |
Custom |
Ask for price |
Fmoc-b-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-Ala-OH |
B-3310.0001 |
Bachem |
1.0g |
EUR 618 |
Description: Sum Formula: C28H27NO6; CAS# [252049-13-1] |
Fmoc-b-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)-Ala-OH |
B-3310.0005 |
Bachem |
5.0g |
EUR 2371.2 |
Description: Sum Formula: C28H27NO6; CAS# [252049-13-1] |
Mouse Monoclonal Anti-Rat CD45RA/B Biotin (Clone OX-33) (mouse IgG1) |
RCD045RAB-B |
Alpha Diagnostics |
100 tests |
EUR 562.8 |
metallo-b-lactamase inhibitor, DNA aptamer, Biotinylated |
AD-159-B |
Alpha Diagnostics |
Custom |
Ask for price |
Multivalent B-cell receptor specific, DNA apatamer, Biotinylated |
AD-156-B |
Alpha Diagnostics |
Custom |
Ask for price |
ODN 2006 (CpG 7909/ODN7909) -Type B-human TLR9 agonist Biotin conjugate-antigen grade |
ODN2006-B |
Alpha Diagnostics |
50 ug |
EUR 270 |
Bovine Cyclophilin B (CYPB) ELISA Kit |
DLR-CYPB-b-48T |
DL Develop |
48T |
EUR 656.4 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Cyclophilin B (CYPB) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Bovine Cyclophilin B (CYPB) ELISA Kit |
DLR-CYPB-b-96T |
DL Develop |
96T |
EUR 858 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Cyclophilin B (CYPB) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Bovine Fetuin B (FETUB) ELISA Kit |
DLR-FETUB-b-48T |
DL Develop |
48T |
EUR 682.8 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Fetuin B (FETUB) in samples from serum, plasma or other biological fluids. |
Bovine Fetuin B (FETUB) ELISA Kit |
DLR-FETUB-b-96T |
DL Develop |
96T |
EUR 895.2 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Fetuin B (FETUB) in samples from serum, plasma or other biological fluids. |
Bovine Cyclophilin B (CYPB) ELISA Kit |
RD-CYPB-b-48Tests |
Reddot Biotech |
48 Tests |
EUR 666 |
Bovine Cyclophilin B (CYPB) ELISA Kit |
RD-CYPB-b-96Tests |
Reddot Biotech |
96 Tests |
EUR 925.2 |
Bovine Cyclophilin B (CYPB) ELISA Kit |
RDR-CYPB-b-48Tests |
Reddot Biotech |
48 Tests |
EUR 696 |
Bovine Cyclophilin B (CYPB) ELISA Kit |
RDR-CYPB-b-96Tests |
Reddot Biotech |
96 Tests |
EUR 968.4 |
Bovine Fetuin B (FETUB) ELISA Kit |
RDR-FETUB-b-48Tests |
Reddot Biotech |
48 Tests |
EUR 728.4 |
Bovine Fetuin B (FETUB) ELISA Kit |
RDR-FETUB-b-96Tests |
Reddot Biotech |
96 Tests |
EUR 1014 |
Bovine Fetuin B (FETUB) ELISA Kit |
RD-FETUB-b-48Tests |
Reddot Biotech |
48 Tests |
EUR 696 |
Bovine Fetuin B (FETUB) ELISA Kit |
RD-FETUB-b-96Tests |
Reddot Biotech |
96 Tests |
EUR 968.4 |
LEXSY Hygro, Hygromycin B, 1 ml (100 mg/ml) ** shipped on blue ice - must be shipped via overnight service |
M-AB-104S |
MiTeGen |
1 ml |
EUR 76 |
|
Description: LEXSY Hygro, Hygromycin B, 1 ml (100 mg/ml) ** shipped on blue ice - must be shipped via overnight service |
Platelet-Derived Growth Factor B-chain (36t), DNA Aptamer, Biotinylated |
AD-136-B |
Alpha Diagnostics |
Custom |
Ask for price |
NATtrol Influenza A/B Positive Control (6 X 0.5 mL) |
NATFLUA/B-6MC |
Zeptometrix |
6 X 0.5 mL |
EUR 278.4 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
HCV NS4 recombinant antigen NS4a+b, Biotin |
00116-V-B-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
HCV NS4 recombinant antigen NS4a+b, Biotin |
00116-V-B-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
Recombinant Hepatitis C HCV NS4 a+b Protein, Biotin, E.coli-100ug |
QP12178-B-100ug |
EnQuireBio |
100ug |
EUR 381.6 |
Recombinant Hepatitis C HCV NS4 a+b Protein, Biotin, E.coli-1mg |
QP12178-B-1mg |
EnQuireBio |
1mg |
EUR 1873.2 |
Recombinant Hepatitis C HCV NS4 a+b Protein, Biotin, E.coli-500ug |
QP12178-B-500ug |
EnQuireBio |
500ug |
EUR 1154.4 |
LEXSY Hygro, Hygromycin B, 5 x 1 ml (100 mg/ml) ** shipped on blue ice - must be shipped via overnight service |
M-AB-104L |
MiTeGen |
5 x 1 ml |
EUR 259 |
|
Description: LEXSY Hygro, Hygromycin B, 5 x 1 ml (100 mg/ml) ** shipped on blue ice - must be shipped via overnight service |
Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) ELISA Kit |
DLR-Bcl2-b-48T |
DL Develop |
48T |
EUR 591.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids. |
Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) ELISA Kit |
DLR-Bcl2-b-96T |
DL Develop |
96T |
EUR 769.2 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids. |
Bovine Vascular Endothelial Growth Factor B (VEGFB) ELISA Kit |
DLR-VEGFB-b-48T |
DL Develop |
48T |
EUR 591.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Vascular Endothelial Growth Factor B (VEGFB) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Bovine Vascular Endothelial Growth Factor B (VEGFB) ELISA Kit |
DLR-VEGFB-b-96T |
DL Develop |
96T |
EUR 769.2 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Vascular Endothelial Growth Factor B (VEGFB) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
We identify PIK3CA, RHOA, MAPK3, PAFAY1B1, CTNNB1, MYC, PRKCA, ERBB2, and CDC42 as a key gene on the MIR-375 network which is set and estimates the possible function of the MIR-375 in the heart muscle, which consists mainly in regulations on signaling paths that are dependent on on RHO-GTPases. We apply our algorithm to predict Mirna’s function into the python module, which is available at GitHub.